A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms ELARA
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 26 Nov 2018 Planned End Date changed from 17 Aug 2022 to 24 Aug 2022.
- 26 Nov 2018 Planned primary completion date changed from 12 Feb 2021 to 19 Feb 2021.
- 05 Sep 2018 Planned End Date changed from 7 Apr 2022 to 17 Aug 2022.